The Ceará, of the first division of the Brazilian soccer, reported this Thursday that there are 17 people with the new coronavirus, among them nine players, as reported by the team from the city of Fortaleza without disclosing names.
In a release, the club stated that four other players are suspected of having been infected and like those nine confirmed how infected they were separated from activities and they must remain in quarantine for fourteen days with medical accompaniment.
The club noted that two other players they had tested positive and five members of the technical staff are already recovered and they are with the rest of the staff doing the physical workss prior to the resumption of the Cearense Championship, the regional tournament, and the start of the Brazilian league, both with no date for their return. The team made 148 rapid tests and 69 PCR for all staff and administrative staff, as well as family and club employees.
This Thursday, the defender Leo, from Cruzeiro, relegated to the second division, he became the third player of the Belo Horizonte team in test positive for COVID-19, adding the attacker Popó and the midfielder Jean.
The last Monday, the players of the Vasco da Gama They returned to their training center in Rio de Janeiro, after two months of social isolation, to restart activities and despite the fact that 19 cast members contracted the new coronavirus. Vasco is the club with the highest number of infected players among the teams in the state of Rio de Janeiro who have made the test results public. After Vasco, the clubs with the most infected athletes are Nova Iguaçu (8), Bangú (7), Flamengo (5), América (3) and Portuguesa (2).
However, the Flamengo records 38 cases when the members of the coaching staff, club employees and relatives and people who live with the players are taken into account. The masseuse of the professional team of Flamengo, Jorginho, died in early May victim of COVID-19, and the Portuguese technician Jorge Jesús was suspected of contagion, which was ruled out in a second clinical test.